Onkologie. 2017:11(6):281-285 | DOI: 10.36290/xon.2017.051

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer

Martin Stašek1, Dušan Klos1, Radmila Lemstrová2, Čestmír Neoral2
1 I. chirurgická klinika LF UP a FN Olomouc
2 Onkologická klinika LF UP a FN Olomouc

Gastric cancer is a serious disease frequently diagnosed at an advanced stage. A significant tendency to peritoneal disseminationwith a significant negative effect on survival is the idea leading to the effort to affect the peritoneal component of the disease.Radical multimodal therapy including chemotherapy, cytoreductive surgical therapy and hypertermic intraperitoneal chemotherapy(HIPEC) is currently under consideration in several studies. The most common indications include limited peritonealspread, Krukenberg tumor, T3 and T4 tumor stage, diffuse carcinoma with scirrhotic growth, lymph node involvement, lowtumor differentiation, perforated carcinoma and positive cytology findings in peritoneal lavage. A slight increase in morbidityand comparable mortality make the procedure acceptable in safety. Repeatedly, prolongation of long-term survival and eventhe possibility of curative effect in limited carcinomatosis have been confirmed. In the future, further widening of the indicationcriteria and clarifying the benefits of HIPEC for both manifest and prophylactic indications can be expected.

Keywords: gastric cancer, carcinomatosis abdominal, hyperthermic intraperitoneal chemotherapy

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stašek M, Klos D, Lemstrová R, Neoral Č. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. Onkologie. 2017;11(6):281-285. doi: 10.36290/xon.2017.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-E386. Go to original source... Go to PubMed...
    2. Bass AJ, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513(7517): 202-209. Go to original source... Go to PubMed...
    3. Hundahl SA, Phillips JL, Menck HR, et al. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000; 88(4): 921-932. Go to original source...
    4. Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann.Oncol 2010; 21(Suppl. 5): v50-54. Go to original source... Go to PubMed...
    5. Spolverat G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014; 219(4): 664-675. Go to original source... Go to PubMed...
    6. Roviello F, Caruso S, Neri A, et al. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. EurJSurgOncol 2013; 39(12): 1309-1316. Go to original source... Go to PubMed...
    7. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. JNatl.Compr.Canc.Netw. 2013; 11(5): 531-546. Go to original source... Go to PubMed...
    8. Modrá kniha České onkologické společnosti, 23. aktualizace. Modrá kniha České onkologické společnosti: platnost od 1.3.2017. Brno: Masarykův onkologický ústav, 2017. Dostupné také z: http://www.linkos.cz/informace-pro-praxi/modra-kniha/
    9. Chang JS, Kim KH, Keum KC, et al. Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. JSurgOncol 2016; 114(7): 859-864. Go to original source... Go to PubMed...
    10. Seyfried F, von Rahden BH, Miras AD, et al. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin - a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer 2015; 19(15): 73. Go to original source... Go to PubMed...
    11. Yonemura Y, Endou Y, Sasaki T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol 2010; 36(12): 1131-1138. Go to original source... Go to PubMed...
    12. Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. JSurgOncol 2011; 104(6): 692-698. Go to original source...
    13. Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010; 17(9): 2370-2377. Go to original source... Go to PubMed...
    14. Rau B, Löffler M, Rau HG, et al. Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC). Dostupné z: https://clinicaltrials.gov/ct2/show/NCT02158988.
    15. Maehara Y, Hasuda S, Koga T, et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000; 87(3): 353-357. Go to original source... Go to PubMed...
    16. Ceelen WP, Hesse U, de Hemptinne B, et al. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg. 2000; 87(8): 1006-1015. Go to original source... Go to PubMed...
    17. Honoré C, Goéré D, Messager M, et al. Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: results of a multicentre retrospective study. Eur J Surg Oncol. 2013; 39(3): 235-241. Go to original source... Go to PubMed...
    18. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996; 82: 359-374. Go to original source... Go to PubMed...
    19. Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005; 92: 370-375. Go to original source... Go to PubMed...
    20. Valle M, Federici O, Garofalo A. Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging and treatment. Surg Oncol Clin N Am 2012; 515-531. Go to original source... Go to PubMed...
    21. Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016 Aug; 42(8): 1123-1131. Go to original source... Go to PubMed...
    22. Yonemura Y, Canbay E, Sako S, et al. Management of peritoneal metastases developed from gastric cancer: laparascopic hyperthermic intraperitoneal chemotherapy in neoadjuvant setting. Integr Oncol 2014; 3: 1. Go to original source...
    23. Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraperitoneal peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric cancer. Ann Surg 2009; 250: 242-246. Go to original source... Go to PubMed...
    24. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 2009;15: 311-316. Go to original source... Go to PubMed...
    25. Yonemura Y, Bandou E, Sawa T, et al. A new treatment by neoadjuvant intraperitoneal-systemic chemotherapy and peritonectomy for peritoneal dissemination from gastric cancer. Eur J Surg Oncol 2006; 32(6): 661-665. Go to original source... Go to PubMed...
    26. Yonemura Y, Canbay E, Endou Y, et al. A new bidirectional intraperitoneal and systemic induction chemotherapy (BISIC) for the peritoneal metastasis from gastric cancer in neoadjuvant setting. Integr Cancer Sci Ther Integr Cancer Sci Ther 2014; 1(2): 26-29. Go to original source...
    27. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998; 14: 254-261. Go to original source...
    28. Glehen O, Cotte E, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008; 98: 242-246. Go to original source... Go to PubMed...
    29. Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010; 21: 67-70. Go to original source... Go to PubMed...
    30. Van Der Speeten K, Stuart OA, Sugarbaker PH. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg.Oncol.Clin.N.Am. 2012; 21(4): 577-597. Go to original source... Go to PubMed...
    31. Braam HJ, Schellens JH, Boot H, et al. Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Crit Rev Oncol Hematol 2015; 95(3): 282-296. Go to original source... Go to PubMed...
    32. Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 2014; 14: 183. Go to original source... Go to PubMed...
    33. Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cutoff. Systemic review and meta-analysis. Eur J Surg Oncol 2015; 41(7): 911-919. Go to original source... Go to PubMed...
    34. Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment. Expert Opin 2014; 15: 623-636. Go to original source... Go to PubMed...
    35. Yonemura Y, Canbay E, Sako S, et al. Phase II study of a comprehensive treatment using perioperative chemotherapy combined with cytoreductive surgery for curatively resected gastric cancer patients with positive peritoneal wash cytology. Glob J Gastroenterol Hepatol 2014; 2: 108-113. Go to original source...
    36. Yonemura Y, Elnemr A, Endou Y, et al. Surgical results of patients with peritoneal carcinomatosis treated with cytoreductive surgery using a new technique named aqua dissection. Gastroenterol Res Pract 2012; 10: 521487. Go to original source... Go to PubMed...
    37. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann.Surg.Oncol. 2011; 18(6): 1575-1581. Go to original source... Go to PubMed...
    38. Huang JY, Xu YY, Sun Z, et al. Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac.J Cancer Prev. 2012;13(9): 4379-4385. Go to original source... Go to PubMed...
    39. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10): 2702-2713. Go to original source... Go to PubMed...
    40. Glehen O, Gilly FN, Cotte E. Hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: the end of skepticism? Ann Surg Oncol 2011; 18: 1524-1526. Go to original source... Go to PubMed...
    41. Costa WL Jr., Coimbra FJ, Ribeiro HS, et al. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J.Surg.Oncol. 2012; 19(10): 195. Go to original source... Go to PubMed...
    42. Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2010; 15(2): 85-97. Go to original source... Go to PubMed...
    43. Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010; 116(24): 5608-5618. Go to original source... Go to PubMed...
    44. Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cutoff. Systemic review and meta-analysis. Eur J Surg Oncol 2015; 41(7): 911-919. Go to original source... Go to PubMed...
    45. Canbay E, Yonemura Y. Peritoneal metastases of gastric cancer, peritoneal surface malignancy. A curative approach. In: Canbay E, Yonemura Y, editors. Cham, Heidelberg, New York, Dordrecht, London: Springer; 2015: 69-70. Go to original source...
    46. O'Dwyer S, Verwaal VJ, Sugarbaker PH. Evolution of treatment for peritoneal metastasis from colorectal cancer. J Clin Oncol 2015: 33. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.